Table I.
The association of Cby mRNA expression with clinical features.
| Clinical features | Patients, n | RQ of Cby mRNA | 95% CI | P-value |
|---|---|---|---|---|
| Sex | >0.05 | |||
| Male | 32 | 0.0779 | 0.0697–0.0833 | |
| Female | 13 | 0.0775 | 0.0770–0.0803 | |
| Age, years | >0.05 | |||
| ≤50 | 27 | 0.0777 | 0.0696–0.0825 | |
| >50 | 18 | 0.0781 | 0.0752–0.0808 | |
| T staging | >0.05 | |||
| 1/2 | 24 | 0.0803 | 0.0770–0.0836 | |
| 3/4 | 21 | 0.0775 | 0.0685–0.0797 | |
| Lymph node metastasis | >0.05 | |||
| N0 | 18 | 0.0801 | 0.0752–0.0836 | |
| N1-3 | 27 | 0.0775 | 0.0696–0.0805 | |
| Clinical staging | <0.01 | |||
| I/II | 19 | 0.0810 | 0.0775–0.0896 | |
| III/IV | 26 | 0.0771 | 0.0687–0.0794 | |
| Pathological classification | >0.05 | |||
| WHO I | 9 | 0.0803 | 0.0728–0.0836 | |
| WHO II | 20 | 0.0773 | 0.0760–0.0821 | |
| WHO III | 16 | 0.0776 | 0.0696–0.0805 |
Cby, Chibby; RQ, relative quantity; CI, confidence interval; WHO I, keratinizing squamous cell carcinoma; WHO II, undifferentiated non-keratinizing carcinoma; WHO III, differentiated non-keratinizing carcinoma.